Firm to pay $431 million over patent
From Times Wire Services
Boston Scientific Corp. was ordered to pay $431 million to a New Jersey doctor for infringing a stent patent.
The company will seek to overturn the award by a jury in Marshall, Texas, as “unsupported by both the evidence and the law” and will appeal if necessary, executives said.
The jury found that Taxus Express and Taxus Liberte drug-eluting stents infringe a patent of Bruce Saffran and that the patent was valid, Natick, Mass.-based Boston Scientific said.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
